Insider Selling: Spark Therapeutics Inc. (ONCE) Insider Sells $603,000.00 in Stock
Spark Therapeutics Inc. (NASDAQ:ONCE) insider Katherine A. High sold 10,000 shares of Spark Therapeutics stock in a transaction dated Monday, November 14th. The stock was sold at an average price of $60.30, for a total value of $603,000.00. Following the sale, the insider now directly owns 210,000 shares of the company’s stock, valued at approximately $12,663,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Spark Therapeutics Inc. (NASDAQ:ONCE) opened at 55.39 on Monday. The stock’s market cap is $1.70 billion. The company’s 50-day moving average price is $54.41 and its 200-day moving average price is $53.46. Spark Therapeutics Inc. has a one year low of $21.20 and a one year high of $65.99.
Spark Therapeutics (NASDAQ:ONCE) last issued its quarterly earnings results on Thursday, November 3rd. The company reported ($1.07) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.01) by $0.06. Spark Therapeutics had a negative return on equity of 28.28% and a negative net margin of 441.05%. The business earned $1.30 million during the quarter, compared to analysts’ expectations of $1.26 million. During the same quarter in the previous year, the company posted ($0.70) EPS. The company’s quarterly revenue was up .0% on a year-over-year basis. Analysts forecast that Spark Therapeutics Inc. will post ($4.17) EPS for the current fiscal year.
A number of large investors have recently modified their holdings of the company. Swiss National Bank raised its stake in shares of Spark Therapeutics by 23.2% in the second quarter. Swiss National Bank now owns 36,600 shares of the company’s stock worth $1,871,000 after buying an additional 6,900 shares during the last quarter. Quantbot Technologies LP acquired a new stake in shares of Spark Therapeutics during the second quarter worth about $124,000. California State Teachers Retirement System raised its stake in shares of Spark Therapeutics by 91.2% in the second quarter. California State Teachers Retirement System now owns 35,988 shares of the company’s stock worth $1,840,000 after buying an additional 17,165 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of Spark Therapeutics by 26.3% in the second quarter. Bank of New York Mellon Corp now owns 83,223 shares of the company’s stock worth $4,255,000 after buying an additional 17,321 shares during the last quarter. Finally, Gilder Gagnon Howe & Co. LLC acquired a new stake in shares of Spark Therapeutics during the second quarter worth about $588,000. Institutional investors and hedge funds own 81.69% of the company’s stock.
Several equities research analysts have issued reports on ONCE shares. Jefferies Group reaffirmed a “hold” rating on shares of Spark Therapeutics in a research note on Friday, August 5th. Wedbush reaffirmed an “underperform” rating and set a $29.00 price target (up previously from $28.00) on shares of Spark Therapeutics in a research note on Wednesday, August 10th. Zacks Investment Research upgraded Spark Therapeutics from a “hold” rating to a “buy” rating and set a $66.00 price objective on the stock in a report on Thursday, August 11th. Cantor Fitzgerald reiterated a “buy” rating and issued a $94.00 price objective on shares of Spark Therapeutics in a report on Thursday, August 11th. Finally, Stifel Nicolaus initiated coverage on Spark Therapeutics in a report on Friday, September 2nd. They issued a “buy” rating and a $73.00 price objective on the stock. Three analysts have rated the stock with a sell rating, four have given a hold rating and seven have given a buy rating to the company’s stock. Spark Therapeutics currently has an average rating of “Hold” and a consensus target price of $60.75.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc (Spark) is engaged in developing products in the field of gene therapy. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its SPK-RPE65 (voretigene neparvovec) targets genetic blinding conditions known as inherited retinal dystrophies (IRDs).
Receive News & Stock Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related stocks with our FREE daily email newsletter.